RARS2

Across TCGA pan-cancer cohorts, RARS2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RARS2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RARS2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RARS2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where RARS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RARS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.510	<.001	11	view →
PDAC	Female	All	−0.975	<.001	7	view →
LSCC	All	All	+0.215	<.001	7	view →
COAD	Male	III,IV	+0.243	.014	2	view →
HNSC	Male	IV	−0.158	.034	2	view →
LUAD	Male	III,IV	+0.210	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RARS2–CCRCC

Open the CCRCC breakdown →